Livforsakringsbolaget Skandia Omsesidigt Buys 7,095 Shares of Natera, Inc. $NTRA

Key Points

• Livforsakringsbolaget Skandia Omsesidigt increased its stake in Natera, Inc. by 788.3% in Q2, acquiring nearly 7,100 additional shares, bringing its total to 7,995 shares valued at approximately $1.35 million.
• Natera's quarterly financial performance showed a revenue growth of 32.2% year-over-year, despite reporting a loss of ($0.74) earnings per share, which was below analysts' estimates.
• Analysts maintain a positive outlook on Natera, with a consensus rating of "Buy" and a price target averaging $194.00, indicating expected continued growth despite recent insider selling activity.

Livforsakringsbolaget Skandia Omsesidigt lifted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 788.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,995 shares of the medical research company's stock after purchasing an additional 7,095 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in Natera were worth $1,351,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bank of Jackson Hole Trust purchased a new stake in Natera during the 1st quarter valued at about $29,000. Oliver Lagore Vanvalin Investment Group bought a new position in Natera during the 2nd quarter valued at approximately $36,000. Rakuten Securities Inc. raised its position in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the last quarter. TCTC Holdings LLC raised its position in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the last quarter. Finally, ORG Partners LLC bought a new position in Natera during the 1st quarter valued at approximately $32,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NTRA stock traded down $1.81 during trading hours on Monday, hitting $179.31. The stock had a trading volume of 663,691 shares, compared to its average volume of 1,449,156. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The stock's 50-day moving average price is $156.80 and its two-hundred day moving average price is $155.19. The stock has a market capitalization of $24.61 billion, a price-to-earnings ratio of -93.88 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period last year, the firm posted ($0.30) earnings per share. The company's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director directly owned 6,015 shares of the company's stock, valued at $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John Fesko sold 678 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total value of $105,401.88. Following the sale, the insider directly owned 152,747 shares in the company, valued at $23,746,048.62. The trade was a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,423 shares of company stock valued at $8,459,656 over the last ninety days. 5.63% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NTRA shares. Barclays reissued an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Wells Fargo & Company started coverage on Natera in a research report on Monday. They set an "equal weight" rating and a $175.00 price objective for the company. Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Stephens reissued an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $192.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.